Oct. 22 at 11:55 AM
$NVAX 🚨
$NVAX just dumped a site for
$60 M cash and chopped
$230 M in future costs.
CEO calls it “leaner and more agile.”
That’s not cost cutting — that’s house-cleaning before company shows up with a checkbook. 💼
Shah Capital’s been whispering “strategic options” for months.
Add the new peer-reviewed mucosal immunity data (IgA antibodies — the real deal) and you’ve got a biotech that suddenly looks 🔥 to Big Pharma.
$CSL?
$GSK? Sanofi?
$SNY $MRK or Serum Institute? Someone’s running the numbers. 🧮
The street’s asleep. Shorts are drunk.
Watch what happens when the phone rings. ☎️
#NVAX #Novavax #M&A #TakeoverWatch #Biotech #ShortSqueeze #ScienceWins next
$BYND